Skip to main content

Payers' Guide

Payers' Guide, FDA Approvals

Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes

Payers' Guide, FDA Approvals

Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes

Payers' Guide, FDA Approvals

Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death

Payers' Guide, FDA Approvals

Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

Once-Fatal Conditions Have Become Chronic: Early Trends in the FDA’s 2015 Approvals

Gary Branning, MBA

Payers' Guide, FDA Approvals

Glyxambi (Empagliflozin/Linagliptin): A Dual- Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes

Lisa A. Raedler, PhD, RPh

Page 13 of 19
Results 121 - 130 of 185